Pediatrix Medical Group Past Earnings Performance
Past criteria checks 0/6
Pediatrix Medical Group's earnings have been declining at an average annual rate of -29.4%, while the Healthcare industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 0.2% per year.
Key information
-29.4%
Earnings growth rate
-29.1%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 0.2% |
Return on equity | -35.7% |
Net Margin | -12.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?
Nov 17These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well
Oct 23Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Oct 08Revenue & Expenses Breakdown
How Pediatrix Medical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,002 | -252 | 227 | 0 |
31 Mar 24 | 1,999 | -71 | 229 | 0 |
31 Dec 23 | 1,995 | -60 | 228 | 0 |
30 Sep 23 | 2,012 | 88 | 226 | 0 |
30 Jun 23 | 1,995 | 95 | 226 | 0 |
31 Mar 23 | 1,981 | 98 | 229 | 0 |
31 Dec 22 | 1,972 | 63 | 231 | 0 |
30 Sep 22 | 1,957 | 79 | 239 | 0 |
30 Jun 22 | 1,960 | 82 | 248 | 0 |
31 Mar 22 | 1,947 | 82 | 258 | 0 |
31 Dec 21 | 1,911 | 108 | 263 | 0 |
30 Sep 21 | 1,829 | 72 | 259 | 0 |
30 Jun 21 | 1,797 | 38 | 259 | 0 |
31 Mar 21 | 1,739 | 14 | 248 | 0 |
31 Dec 20 | 1,734 | -10 | 249 | 0 |
30 Sep 20 | 1,776 | -4 | 253 | 0 |
30 Jun 20 | 1,770 | 11 | 250 | 0 |
31 Mar 20 | 1,678 | 1 | 230 | 0 |
31 Dec 19 | 1,780 | 42 | 245 | 0 |
30 Sep 19 | 2,210 | 94 | 291 | 0 |
30 Jun 19 | 2,603 | 143 | 323 | 0 |
31 Mar 19 | 3,145 | 221 | 384 | 0 |
31 Dec 18 | 1,723 | 122 | 232 | 0 |
30 Sep 18 | 3,477 | 333 | 450 | 0 |
30 Jun 18 | 3,497 | 337 | 456 | 0 |
31 Mar 18 | 3,475 | 326 | 458 | 0 |
31 Dec 17 | 3,253 | 305 | 386 | 0 |
30 Sep 17 | 3,378 | 262 | 443 | 0 |
30 Jun 17 | 3,337 | 293 | 435 | 0 |
31 Mar 17 | 3,266 | 312 | 424 | 0 |
31 Dec 16 | 3,183 | 325 | 411 | 0 |
30 Sep 16 | 3,094 | 340 | 393 | 0 |
30 Jun 16 | 2,988 | 334 | 379 | 0 |
31 Mar 16 | 2,893 | 336 | 360 | 0 |
31 Dec 15 | 2,780 | 336 | 338 | 0 |
30 Sep 15 | 2,689 | 332 | 316 | 0 |
30 Jun 15 | 2,593 | 327 | 296 | 0 |
31 Mar 15 | 2,512 | 322 | 285 | 0 |
31 Dec 14 | 2,439 | 317 | 275 | 0 |
30 Sep 14 | 2,356 | 308 | 262 | 0 |
30 Jun 14 | 2,284 | 299 | 256 | 0 |
31 Mar 14 | 2,218 | 289 | 250 | 0 |
31 Dec 13 | 2,154 | 281 | 245 | 0 |
30 Sep 13 | 2,058 | 268 | 237 | 0 |
Quality Earnings: MD is currently unprofitable.
Growing Profit Margin: MD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MD is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.
Accelerating Growth: Unable to compare MD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8%).
Return on Equity
High ROE: MD has a negative Return on Equity (-35.65%), as it is currently unprofitable.